TY - JOUR
T1 - Agonist replacement for stimulant dependence
T2 - a review of clinical research.
AU - Stoops, William W.
AU - Rush, Craig R.
PY - 2013
Y1 - 2013
N2 - Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and clinical trials to determine whether agonist replacement therapy is a viable strategy for managing cocaine and/or amphetamine use disorders. The extant literature suggests that agonist replacement therapy may be effective for managing stimulant use disorders, however, the clinical selection of an agonist replacement medication likely needs to be based on the pharmacological mechanism of the medication and the stimulant abused by patients. Specifically, dopamine releasers appear most effective for reducing cocaine use whereas dopamine reuptake inhibitors appear most effective for reducing amphetamine use.
AB - Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and clinical trials to determine whether agonist replacement therapy is a viable strategy for managing cocaine and/or amphetamine use disorders. The extant literature suggests that agonist replacement therapy may be effective for managing stimulant use disorders, however, the clinical selection of an agonist replacement medication likely needs to be based on the pharmacological mechanism of the medication and the stimulant abused by patients. Specifically, dopamine releasers appear most effective for reducing cocaine use whereas dopamine reuptake inhibitors appear most effective for reducing amphetamine use.
UR - http://www.scopus.com/inward/record.url?scp=84906796674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906796674&partnerID=8YFLogxK
U2 - 10.2174/138161281940131209142843
DO - 10.2174/138161281940131209142843
M3 - Review article
C2 - 23574440
AN - SCOPUS:84906796674
SN - 1381-6128
VL - 19
SP - 7026
EP - 7035
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 40
ER -